Replies to post #1808 on Viking Therapeutics Inc (VKTX)

[roadkilll]

Impressed with the 5mg data and really hoping for a 2.5mg arm in coming trial

Comparison of Madrigal's drug and Viking is even more encouraging

Madrigal's ß SELECTIVE AGONIST FOR NASH
Molecular Weight: 435.22 and dosage of 100mg

Viking"s ß SELECTIVE AGONIST FOR NASH
Molecular Weight : 514.98 and dosage of 5mg

Viking's VK2809 more ß selective and can be used at a lower dose? And, nobody is ruling out a 2.5mg dose. The lower the dose the fewer off target hits you get and better odds of a more effective safer drug. Madrigal's MGL-3196 (resmetirom) had very impressive biopsy based phased 2 trial showing till then unprecedented liver fat reduction and fibrosis reduction, just not nearly as good as Vikings VK2809.

Looks like MDGL and VKTX are going to be winners for investors, 2H19 is going to be interesting